13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001274413
Total reported value
$143.3M
$143.3M
86 檔
43.1%
During the Q4 2024 filing period, Sectoral Asset Management Inc (CIK: 0001274413) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $143.3M across 86 reported positions.
In Q4 2024, Sectoral Asset Management Inc adopted a defensive or profit-taking posture, trimming 55 positions and completely liquidating 13 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | Stock-Other | 18.83% | — | — | |
| 2 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 7.83% | +0.45% | -0.01% | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.46% | +0.48% | +14.10% | |
| 4 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 4.94% | +0.49% | +11.43% | |
| 5 | GILD | Gilead Sciences Inc | Stock-Healthcare | 3.16% | -1.60% | -15.97% | |
| 6 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.13% | -0.47% | +15.59% | |
| 7 | ABBV | Abbvie Inc | Stock-Healthcare | 2.23% | -0.06% | +18.99% | |
| 8 | JNJ | Johnson & Johnson | Stock-Healthcare | 2.21% | -0.46% | -11.58% | |
| 9 | AMGN | Amgen Inc | Stock-Healthcare | 2.18% | -0.58% | +77.01% | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.94% | -0.73% | -1.51% | |
| 11 | ABT | Abbott Laboratories | Stock-Healthcare | 1.84% | -1.04% | +25.78% | |
| 12 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.66% | -0.21% | -12.00% | |
| 13 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.65% | -0.20% | -9.52% | |
| 14 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.63% | -0.20% | +2.08% | |
| 15 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.62% | -1.12% | — | |
| 16 | SYK | Stryker CORP | Stock-Healthcare | 1.54% | -0.03% | -14.09% | |
| 17 | BNTX | Biontech Se-adr | Stock-Other | 1.44% | +1.03% | +44.05% | |
| 18 | MDT | Medtronic plc | Stock-Healthcare | 1.41% | -0.19% | -10.22% | |
| 19 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.41% | -0.44% | -14.19% | |
| 20 | PFE | Pfizer Inc | Stock-Healthcare | 1.37% | -0.18% | -32.27% | |
| 21 | BOLD | Boundless Bio Inc | Stock-Other | 1.31% | -0.62% | EXIT | |
| 22 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.30% | -0.23% | -14.34% | |
| 23 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.29% | -0.12% | -20.26% | |
| 24 | DHR | Danaher CORP | Stock-Healthcare | 1.12% | -0.23% | +52.36% | |
| 25 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.08% | -0.28% | EXIT | |
| 26 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.06% | -0.38% | — | |
| 27 | PCVX | Vaxcyte Inc | Stock-Other | 1.04% | — | +30.33% | |
| 28 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 0.99% | -0.98% | -24.17% | |
| 29 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.89% | — | -10.52% | |
| 30 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.89% | -0.43% | +101.89% | |
| 31 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.86% | — | -13.10% | |
| 32 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.85% | — | -4.04% | |
| 33 | QURE | uniQure N.V. | Stock-Other | 0.84% | -0.41% | EXIT | |
| 34 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.78% | — | -38.52% | |
| 35 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.77% | +0.52% | -14.31% | |
| 36 | HCAT | Health Catalyst Inc | Stock-Other | 0.76% | — | — | |
| 37 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.75% | -0.13% | +79.65% | |
| 38 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.75% | -0.39% | +7.47% | |
| 39 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.73% | — | -15.82% | |
| 40 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.69% | +1.53% | -7.91% | |
| 41 | PRVA | Privia Health Group Inc | Stock-Other | 0.68% | -0.03% | — | |
| 42 | CVS | Cvs Health CORP | Stock-Healthcare | 0.66% | +0.94% | NEW | |
| 43 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.65% | — | +9.56% | |
| 44 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 0.64% | — | -31.35% | |
| 45 | CLOV | Clover Health Investments Co | Stock-Other | 0.58% | — | — | |
| 46 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 0.54% | — | -47.37% | |
| 47 | NARIUSD | Inari Medical Inc | Stock-Other | 0.52% | — | -39.39% | |
| 48 | CI | THE Cigna Group | Stock-Healthcare | 0.41% | — | — | |
| 49 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.40% | — | — | |
| 50 | BIIB | Biogen Inc | Stock-Healthcare | 0.39% | -0.04% | -36.09% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LENZ | Lenz Therapeutics Inc | +5.1% | — | Unchanged |
| 2 | AMGN | Amgen Inc | +0.8% | +77.01% | Add |
| 3 | MLYS | Mineralys Therapeutics Inc | +0.8% | +15.59% | Add |
| 4 | HCAT | Health Catalyst Inc | +0.8% | NEW | New buy |
| 5 | LLY | Eli Lilly & Co | +0.7% | +14.10% | Add |
| 6 | PRVA | Privia Health Group Inc | +0.7% | NEW | New buy |
| 7 | CLOV | Clover Health Investments Co | +0.6% | NEW | New buy |
| 8 | TARS | Tarsus Pharmaceuticals Inc | +0.5% | +79.65% | Add |
| 9 | ABT | Abbott Laboratories | +0.5% | +25.78% | Add |
| 10 | BNTX | Biontech Se-adr | +0.5% | +44.05% | Add |
| 11 | CI | THE Cigna Group | +0.4% | NEW | New buy |
| 12 | UNH | Unitedhealth Group Inc | +0.4% | +11.43% | Add |
| 13 | IOVA | Iovance Biotherapeutics Inc | +0.4% | NEW | New buy |
| 14 | QURE | uniQure N.V. | +0.4% | -53.27% | Trim |
| 15 | ABBV | Abbvie Inc | +0.4% | +18.99% | Add |
| 16 | DHR | Danaher CORP | +0.3% | +52.36% | Add |
| 17 | BSX | Boston Scientific CORP | +0.3% | -1.51% | Trim |
| 18 | GPCR | Structure Therapeutics Inc | +0.3% | +101.89% | Add |
| 19 | NBIX | Neurocrine Biosciences Inc | +0.2% | -5.71% | Trim |
| 20 | ISRG | Intuitive Surgical Inc | +0.2% | — | Unchanged |
| 21 | GILD | Gilead Sciences Inc | +0.1% | -15.97% | Trim |
| 22 | BMY | Bristol-myers Squibb Co | +0.1% | -12.00% | Trim |
| 23 | ARGX | Argenx Se - Adr | +0.1% | -14.19% | Trim |
| 24 | INCY | Incyte CORP | +0.1% | NEW | New buy |
| 25 | CRGX | Cargo Therapeutics Inc | +0.1% | NEW | New buy |
| 26 | PCVX | Vaxcyte Inc | +0.1% | +30.33% | Add |
| 27 | MLTX | Moonlake Immunotherapeutics | +0.1% | -13.10% | Trim |
| 28 | AXSM | Axsome Therapeutics Inc | +0.1% | NEW | New buy |
| 29 | IOBTQ | Io Biotech Inc | +0.1% | NEW | New buy |
| 30 | GERN | Geron CORP | 0% | +38.04% | Add |
| 31 | MRK | Merck & Co. Inc. | 0% | +2.08% | Add |
| 32 | RCUS | Arcus Biosciences Inc | 0% | -7.91% | Trim |
| 33 | SMMT | Summit Therapeutics Inc | 0% | +12.36% | Add |
| 34 | ✓ | Turnstone Biologics CORP | — | — | Unchanged |
| 35 | PTCT | Ptc Therapeutics Inc | — | -23.68% | Trim |
| 36 | ITCIEUR | Intra-cellular Therapies Inc | 0% | -23.79% | Trim |
| 37 | MDGL | Madrigal Pharmaceuticals Inc | 0% | -45.45% | Trim |
| 38 | JAZZ | Jazz Pharmaceuticals plc | 0% | -23.04% | Trim |
| 39 | SRPT | Sarepta Therapeutics Inc | 0% | -10.52% | Trim |
| 40 | ✓ | Engene Holdings Inc | 0% | -16.24% | Trim |
| 41 | NVO | Novo-nordisk A/s-spons Adr | 0% | — | Unchanged |
| 42 | BBIO | Bridgebio Pharma Inc | 0% | -23.77% | Trim |
| 43 | VERA | Vera Therapeutics Inc | 0% | -23.26% | Trim |
| 44 | MEDP | Medpace Holdings Inc | 0% | -23.57% | Trim |
| 45 | RVMD | Revolution Medicines Inc | 0% | -23.79% | Trim |
| 46 | CRNX | Crinetics Pharmaceuticals In | 0% | -24.14% | Trim |
| 47 | AM6 | Amicus Therapeutics Inc | 0% | -4.04% | Trim |
| 48 | ROIV | Roivant Sciences Ltd. | 0% | -23.55% | Trim |
| 49 | ASND | Ascendis Pharma A/S | 0% | -25.27% | Trim |
| 50 | SYK | Stryker CORP | -0.1% | -14.09% | Trim |
According to official SEC Form 13F filings, Sectoral Asset Management Inc reported a total U.S. public equity portfolio value of $143.3M across 86 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LENZ, CTNM, LLY) accounted for 43.1% of total reported equity market value during Q4 2024.
Top New Position Initiated
HCAT
市值: $1.1M
Top Position Liquidated / Trimmed
IQV
前期市值: $1.8M
During Q4 2024, Sectoral Asset Management Inc's top holdings by market value included LENZ (18.8%)、CTNM (7.8%)、LLY (6.5%). The largest single position, LENZ, represented 18.8% of total portfolio value.
In Q4 2024, Sectoral Asset Management Inc made 93 total portfolio adjustments, initiating 9 new buys, adding to 16 positions, trimming 55 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.